The cell competition-based high-throughput screening identifies small compounds that promote the elimination of RasV12-transformed cells from epithelia
Open Access
- 20 October 2015
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 15336
Abstract
Recent studies have revealed that cell competition can occur between normal and transformed epithelial cells; normal epithelial cells recognize the presence of the neighboring transformed cells and actively eliminate them from epithelial tissues. Here, we have established a brand-new high-throughput screening platform that targets cell competition. By using this platform, we have identified Rebeccamycin as a hit compound that specifically promotes elimination of RasV12-transformed cells from the epithelium, though after longer treatment it shows substantial cytotoxic effect against normal epithelial cells. Among several Rebeccamycin-derivative compounds, we have found that VC1-8 has least cytotoxicity against normal cells but shows the comparable effect on the elimination of transformed cells. This cell competition-promoting activity of VC1-8 is observed both in vitro and ex vivo. These data demonstrate that the cell competition-based screening is a promising tool for the establishment of a novel type of cancer preventive medicine.Keywords
This publication has 28 references indexed in Scilit:
- Filamin acts as a key regulator in epithelial defence against transformed cellsNature Communications, 2014
- Cell competition: how to eliminate your neighboursDevelopment, 2014
- Cortical F-actin stabilization generates apical–lateral patterns of junctional contractility that integrate cells into epitheliaNature Cell Biology, 2014
- PKA-regulated VASP phosphorylation promotes extrusion of transformed cells from the epitheliumJournal of Cell Science, 2014
- Mechanisms and mechanics of cell competition in epitheliaNature Reviews Molecular Cell Biology, 2013
- Mechanisms of cell competition: Themes and variationsJournal of Cell Biology, 2013
- Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung CancerJournal of Thoracic Oncology, 2012
- Outgrowth of single oncogene-expressing cells from suppressive epithelial environmentsNature, 2012
- Interactions between normal and transformed epithelial cells: Their contributions to tumourigenesisThe International Journal of Biochemistry & Cell Biology, 2011
- Cell competitionCurrent Biology, 2011